```
     (FILE 'HOME' ENTERED AT 09:23:44 ON 25 NOV 2002)

     FILE 'EMBASE, BIOSIS, MEDLINE, CAPLUS, USPATFULL' ENTERED AT 09:24:01 ON
     25 NOV 2002
L1         88405 S PDE2 OR PHOSPHODIESTERASE 2 OR PDE OR PHOSPHODIESTERASE
L2        296105 S LUPUS OR AUTOIMMUNE
L3          1706 S L2 AND L1
L4         27894 S PDE2 INHIBITOR OR PHOSPHODIESTERASE 2 INHIBITOR OR PDE
INHIBI
L5           476 S L2 AND L4
L6           287 S L5 AND PY<2001
L7           247 DUP REM L6 (40 DUPLICATES REMOVED)

=> s PDE II or phosphodiesterase II or PDE type 2
L8           922 PDE II OR PHOSPHODIESTERASE II OR PDE TYPE 2

=> s l8 and ;2
MISSING TERM AFTER L8 AND
COMMAND STACK INTERRUPTED.  ENTER "DISPLAY HISTORY"
TO SEE WHICH COMMANDS WERE EXECUTED.

Operators must be followed by a search term, L-number, or query name.

=> s l8 and l2
L9           11 L8 AND L2

=> s l9 and py<2001
   2 FILES SEARCHED...
L10           5 L9 AND PY<2001

=> dup rem l10
PROCESSING COMPLETED FOR L10
L11           5 DUP REM L10 (0 DUPLICATES REMOVED)

=> s l11 1-5 ab bib kwic
MISSING OPERATOR L11 1-5
The search profile that was entered contains terms or
nested terms that are not separated by a logical operator.

=> d l11 1-5 ab bib kwic

L11  ANSWER 1 OF 5  USPATFULL
AB     A combination preparation comprising a compound which has a
       phosphodiesterase-inhibiting action, and a compound which reduces the
       biologically effective intracellular Ca.sup.2+  content, is suitable
for
       the treatment of immunological diseases.
AN     1999:151206  USPATFULL
TI     Combination preparation for use in immunological diseases
IN     Schonharting, Martin, Taunusstein, Germany, Federal Republic of
       Mullner, Stefan, Hochheim, Germany, Federal Republic of
       Zabel, Peter, Bad Segeberg, Germany, Federal Republic of
PA     Hoechst Aktiengesllschaft, Frankfurt am Main, Germany, Federal Republic
       of (non-U.S. corporation)
PI     US 5990103              19991123                                <--
       WO 9605838  19960229                                          <--
AI     US 1997-793417          19970225 (8)
       WO 1995-EP3125          19950807
                               19970225  PCT 371 date
                               19970225  PCT 102(e) date
```

PRAI DE 1994-4430128 19940825
DT Utility
FS Granted
EXNAM Primary Examiner: MacMillan, Keith D.
LREP Foley & Lardner
CLMN Number of Claims: 8
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 614
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
PI US 5990103 19991123 <--
WO 9605838 19960229 <--
SUMM . . . Ca.sup.2+ /calmodulin-dependent PDE I cleaves both cGMP and cAMP and is inhibited e.g. by phenothiazine, vinpocetine or IBMX. The cGMP-stimulatable **PDE II** also cleaves cGMP and cAMP, but no selective inhibitors are known for this enzyme; this is in contrast to PDE III, which has an identical substrate specificity to **PDE II** but can be inhibited by cGMP and a large number of other substances. The sometimes considerable structural differences between PDE. . .
SUMM **autoimmune** diseases, especially rheumatoid arthritis, systemic **lupus** erythematosus and multiple sclerosis;

L11 ANSWER 2 OF 5 USPATFULL
AB This invention provides a method of selectively decreasing pulmonary vascular resistance in a subject by administering endobronchially a drug chosen from among cAMP analogs, cGMP analogs, phosphodiesterase inhibitors, nitric oxide precursors, nitric oxide donors, and nitric oxide analogs.
AN 1999:128527 USPATFULL
TI Method of inducing vasorelaxation to treat pulmonary hypertension
IN Lawson, Charles A., Verona, NJ, United States
Pinsky, David J., Riverdale, NY, United States
Smerling, Arthur, New Rochelle, NY, United States
Stern, David M., Great Neck, NY, United States
PA The Trustees of Columbia University in the City of New York, New York, NY, United States (U.S. corporation)
PI US 5968911 19991019 <--
WO 9509636 19950413 <--
AI US 1997-362571 19970218 (8)
WO 1994-US11248 19941004
19970218 PCT 371 date
19970218 PCT 102(e) date
RLI Continuation-in-part of Ser. No. US 1993-131984, filed on 4 Oct 1993
DT Utility
FS Granted
EXNAM Primary Examiner: Kunz, Gary L.
LREP White, John P.Cooper & Dunham LLP
CLMN Number of Claims: 47
ECL Exemplary Claim: 1
DRWN 19 Drawing Figure(s); 31 Drawing Page(s)
LN.CNT 1790
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
PI US 5968911 19991019 <--
WO 9509636 19950413 <--
DETD . . . this classification is not universal and other classification schemes can be found in the literature.): PDE I - Ca.sup.+2 /Calmodulin-activatable; **PDE II** - cGMP activatable; PDE III - cGMP inhibitable; PDE IV - cAMP-specific; PDE V -

cGMP-specific. These families include, but. . .
DETD . . . were established. Because thromboxane is thought to play a role
in pulmonary hypertension in diseases as varied as scleroderma, systemic
lupus erythematosus, cirrhosis of the liver, and pulmonary emboli (25-33), the thromboxane analog U-46619,9,11-dideoxy-11.alpha.,9.alpha.-epoxymethanoprostaglandin F.sub.2.alpha. (10) was infused to induce pulmonary. . .
DETD . . . relevant to clinical pulmonary hypertension because thromboxane
is thought to play a role in diseases as varied as scleroderma, systemic
lupus erythematosus, cirrhosis of the liver, and pulmonary emboli..sup.27-35 Others have shown that endothelium-derived relaxing factor (nitric oxide) has a significant. . .

L11 ANSWER 3 OF 5 USPATFULL
AB Attaching certain ligands to antisense probes will hyperstabilize sense-antisense duplexes. Such a hyperstabilized duplex is resistant to melting of the strands from one another, to unwinding of the strands, and to the action of nucleases. Applications include antiretroviral action, anti-reverse-transcriptase action, antiviral action, antiparasitical action, antibacterial action, antifungal action, anticancer action, anti-oncogene action, and other applications where it
is desired to inhibit gene expression at the genomic or messenger RNA level. The preferred ligands are certain minor-groove-binding agents, exemplified by CC-1065 and synthetic CC-1065 analogs.
AN 1998:88633 USPATFULL
TI Hyperstabilizing antisense nucleic acid binding agents
IN Swenson, David H., Baton Rouge, LA, United States
PA Board of Supervisors of Louisiana State University and Agricultural and Mechanical College, Baton Rouge, LA, United States (U.S. corporation)
PI US 5786138 19980728 <--
AI US 1994-289130 19940811 (8)
RLI Continuation of Ser. No. US 1993-10408, filed on 29 Jan 1993, now abandoned
DT Utility
FS Granted
EXNAM Primary Examiner: Jones, W. Gary; Assistant Examiner: Rees, Dianne
LREP Runnels, John H.
CLMN Number of Claims: 47
ECL Exemplary Claim: 24
DRWN No Drawings
LN.CNT 1252
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
PI US 5786138 19980728 <--
SUMM . . . is expected to have important therapeutic applications directed
toward a variety of diseases, possibly including cancer, viral and retroviral diseases, **autoimmune** diseases, and parasitic infections.
DETD . . . ligand will be synthesized by following generally the route of Bolton et al., "Synthesis of the Phosphodiesterase Inhibitors PDE-I and **PDE-II**," J. Chem. Soc., Chem. Commun., pp. 1775-1776 (1985), which is incorporated by reference, to produce the following compound (R2=t-butylcarbonyl): ##STR5##
DETD . . . by reference, include those taught generally by Boger et al., "Diels-Alder Reactions of Heterocyclic Azadienes: Total Synthesis of PDE

I, **PDE II**, and PDE I Dimer Methyl Ester," J. Am. Chem. Soc., vol. 109, pp. 2717-2727 (1987); Rawal et al., "Photocyclization Strategy. . . 108, pp. 2110-2112 (1986); Carter et al., "Studies on the Synthesis of the Antitumor Agent CC-1065--Synthesis of PDE I and **PDE II**, Inhibitors of cAMP Phosphodiesterase," J. Chem. Soc., Chem. Commun., pp. 1162-1164 (1986); and Reynolds et al., "The Chemistry, Mechanism of. . .

L11 ANSWER 4 OF 5 USPATFULL

AB Compounds of formula I ##STR1## their physiologically-hydrolyzable and -acceptable esters and salts thereof. Said compounds, esters and pharmaceutically acceptable acid addition salts are useful as pharmaceuticals, e.g. for asthma therapy.

AN 1998:48424 USPATFULL

TI Isoquinoline compounds, compositions containing them and their pharmaceutical uses

IN Naef, Reto, Rheinfelden, Switzerland

PA Novartis AG, Basel, Switzerland (non-U.S. corporation)

PI US 5747506 19980505 <--

AI US 1996-771556 19961220 (8)

RLI Continuation of Ser. No. US 1995-472042, filed on 6 Jun 1995, now abandoned which is a continuation of Ser. No. US 1994-333699, filed on 3 Nov 1994, now abandoned

PRAI GB 1993-22828 19931105

DT Utility

FS Granted

EXNAM Primary Examiner: Davis, Zinna Northington

LREP Borovian, Joseph J.

CLMN Number of Claims: 16

ECL Exemplary Claim: 1

DRWN No Drawings

LN.CNT 873

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

PI US 5747506 19980505 <--

DETD . . . of cAMP 1 .mu.M can be stimulated by Ca.sup.2+ +calmodulin (0.5 mM and 125 nM, respectively); eluting at 0.17-0.18M NaCl. **PDE II**: fractions showing substantial cAMP hydrolytic activity at 100 .mu.M but not at 1 .mu.M; eluting at 0.31-0.32M NaCl. PDE V:. . .

DETD . . . well as their immunosuppressive activity, AGENTS OF THE INVENTION are also useful as immunosuppressive agents, e.g. for the treatment of **autoimmune** diseases, in particular for the treatment of **autoimmune** diseases in which inflammatory processes are implicated or which have an inflammatory component or aetiology, or as anti-inflammatory agents for the treatment of inflammatory disease in particular for the treatment of inflammatory disease in which **autoimmune** reactions are implicated or having an **autoimmune** component or aetiology.

DETD Examples of such disease to which the present invention is applicable include **autoimmune** hematological disorders (e.g. hemolytic anemia, aplastic anemia, pure red cell anemia and idiopathic thrombocytopenia), systemic **lupus** erythematosus, polychondritis, sclerodoma, Wegener granulamatosis, dermatomyositis, chronic active hepatitis, myasthenia gravis, Steven-Johnson syndrome, idiopathic sprue, **autoimmune** inflammatory bowel disease (e.g. ulcerative colitis and Crohn's disease) endocrine ophthalmopathy, Grave's disease, sarcoidosis, alveolitis, chronic hypersensitivity pneumonitis, multiple sclerosis,. . .

DETD . . . the treatment of endotoxin shock; nasally, for example for the treatment of rhinitis; occularly, for example for the treatment of **autoimmune** diseases of the eye; dermally, i.e. topically to the skin, for example for the treatment of dermatosese or psoriasis; or. . .

L11 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2002 ACS

AB Poly-ADP-ribose (fraction III: [ADP-ribose]n (n > 20) (I) was isolated from the serum of patients with systemic **lupus** erythematosus or synthesized using NMN, [14C]ATP, and calf thymus nucleus, followed by fractionation by hydroxy apatite column chromatog. I was conjugated with methylated bovine serum albumin, and injected i.p. into BALB/c mice. Spleen cells of immunized mice and mouse bone marrow cells (Ns-1) were incubated in 50% polyethyleneglycol. The antibody-producing cloned hybridoma cells (10H and 16B) were isolated and proliferated by i.p. injection in BALB/c mice. The supernatant of the in vitro culture of the cloned hybridomas was treated with (NH4)2SO4 at 0.5 satn., and the ppt. was chromatographed on an I-conjugated Sepharose 4B column, followed by elution with 3M Na thiocyanate. The isotype of 10H and 16B antibodies was identified as IgG3 .kappa., and IgM .lambda., resp. 10H antibody showed much higher immunoreactivity with I than 16B antibody. The immunoreactivity of 10H antibody was interfered with by smaller poly-ADP-ribose and slightly by monomeric ADP-ribose. 14C-labeled I was incubated with 10H or 16B antibody, and unreacted 14C-labeled I in the supernatant was digested with venom **phosphodiesterase** (**II**), followed by DEAE-Sephadex A-25 column chromatog. or degraded by II plus alk. phosphatase digestion, followed by paper chromatog.

AN 1984:549475 CAPLUS

DN 101:149475

TI Analysis of the structure of poly(ADP-ribose) recognized by monoclonal antibodies

AU Kawamitsu, Hisae

CS Dep. Intern. Med., Tokyo Med. Dent. Univ., Tokyo, Japan

SO Ochanomizu Igaku Zasshi (**1984**), 32(2), 173-81
CODEN: OCIZAD; ISSN: 0472-4674

DT Journal

LA Japanese

SO Ochanomizu Igaku Zasshi (**1984**), 32(2), 173-81
CODEN: OCIZAD; ISSN: 0472-4674

AB Poly-ADP-ribose (fraction III: [ADP-ribose]n (n > 20) (I) was isolated from the serum of patients with systemic **lupus** erythematosus or synthesized using NMN, [14C]ATP, and calf thymus nucleus, followed by fractionation by hydroxy apatite column chromatog. I was conjugated with methylated bovine serum albumin, and injected i.p. into BALB/c mice. Spleen cells of immunized mice and mouse bone marrow cells (Ns-1) were incubated in 50% polyethyleneglycol. The antibody-producing cloned hybridoma cells (10H and 16B) were isolated and proliferated by i.p. injection in BALB/c mice. The supernatant of the in vitro culture of the cloned hybridomas was treated with (NH4)2SO4 at 0.5 satn., and the ppt. was chromatographed on an I-conjugated Sepharose 4B column, followed by elution with 3M Na thiocyanate. The isotype of 10H and 16B antibodies was identified as IgG3 .kappa., and IgM .lambda., resp. 10H antibody showed much higher immunoreactivity with I than 16B antibody. The immunoreactivity of 10H antibody was interfered with by smaller poly-ADP-ribose and slightly by monomeric ADP-ribose. 14C-labeled I was incubated with 10H or 16B antibody, and unreacted 14C-labeled I in the supernatant was digested with venom **phosphodiesterase** (**II**), followed by DEAE-Sephadex A-25 column chromatog. or degraded

by II plus alk. phosphatase digestion, followed by paper chromatog.

=>